Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 24;23(9):1379–1392. doi: 10.1038/s41590-022-01290-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 4 — (a) Evaluation of cell proliferation/viability by CellTiter-Glo® assay in parental (PAR) and FACS-isolated CD133⁺CD24⁺CD44^+low (CD44L) and CD133⁺CD24⁺CD44^+high (CD44H) MCA205 cells (upon enrichment via IFN-I administration) treated for 72 h with oxaliplatin (OXP), doxorubicin (DOX) and mitoxantrone (MTX) as indicated. Results are reported as mean ± s.e.m., n = 3 biologically independent experiments. (b) In vivo evaluation of the prophylactic potential of PAR MCA205 and immunogenic cell death (ICD)-induced CSCs by using immunocompetent C57Bl/6J (Wild-type/Wt) mice or immunodeficient NSG mice that rejected the injections with PAR, CD44H and CD44L cells at the indicated dose in the experiment reported in Fig. 4b and rechallenging the animals with 1 × 10⁵ PAR MCA205 in the other flank. The percentage of tumor-free mice is shown. (c) Ex vivo flow cytometric analysis of CD4 and CD8 expression in splenocytes from C57Bl/6J mice treated intraperitoneally with vehicle (CTR) or 200 µg/mouse of anti-CD4 and anti-CD8 (200 µg/mouse at day -1 and then every 4 days for 2 weeks). One representative experiment out of two is shown. (d) Schematic representation of ‘competition’ microfluidic devices. CD24L, CD133⁺CD44⁺CD24^+low. (a) Ordinary one-way ANOVA test followed by Bonferroni’s correction. (b) Log-rank (Mantel-Cox) test.

Source data